Johnson & Johnson submitted an application to the Food and Drug Administration Thursday for an emergency use authorization for its experimental Covid-19 vaccine.
The FDA could grant that authorization within weeks. If authorized, it would give the U.S. a third Covid-19 vaccine, along with the vaccines from Pfizer-BioNTech and Moderna.
"Today's submission for emergency use authorization of our investigational single-shot Covid-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic," Dr. Paul Stoffels, chief scientific officer at Johnson & Johnson, said in a press release.
If the FDA grants the company emergency use authorization, Stoffels said the company would be ready to begin shipping vaccines. It is unclear how many doses would be ready immediately, however Johnson & Johnson previously said it expects to supply 100 million doses to the U.S. by June.
The Johnson & Johnson vaccine, made in partnership with Janssen Pharmaceuticals, only requires basic refrigeration and is given as a single dose. Other vaccines, including Pfizer and Moderna's shots, as well as vaccines being studied from AstraZeneca and Novavax, require two doses.
In Phase 3 clinical trials, the Johnson & Johnson vaccine prevented all hospitalizations and deaths in people four weeks after they received the shot, the company said last week. Notably, these effects were observed in people infected with virus variants from the U.K. and South Africa, which can hinder vaccine efficacy.
Indeed, that was apparent when the Phase 3 clinical trial findings were broken down by region. In the U.S., the vaccine was 72 percent effective at preventing moderate to severe disease, while in South Africa, it was 57 percent effective.
When researchers looked just at the shot's effect on severe disease, it was shown to be 85 percent effective, globally. ...
